205 related articles for article (PubMed ID: 22053108)
1. Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms.
Score J; Hidalgo-Curtis C; Jones AV; Winkelmann N; Skinner A; Ward D; Zoi K; Ernst T; Stegelmann F; Döhner K; Chase A; Cross NC
Blood; 2012 Feb; 119(5):1208-13. PubMed ID: 22053108
[TBL] [Abstract][Full Text] [Related]
2. Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies.
Puda A; Milosevic JD; Berg T; Klampfl T; Harutyunyan AS; Gisslinger B; Rumi E; Pietra D; Malcovati L; Elena C; Doubek M; Steurer M; Tosic N; Pavlovic S; Guglielmelli P; Pieri L; Vannucchi AM; Gisslinger H; Cazzola M; Kralovics R
Am J Hematol; 2012 Mar; 87(3):245-50. PubMed ID: 22190018
[TBL] [Abstract][Full Text] [Related]
3. Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27.
Kirmizis A; Bartley SM; Kuzmichev A; Margueron R; Reinberg D; Green R; Farnham PJ
Genes Dev; 2004 Jul; 18(13):1592-605. PubMed ID: 15231737
[TBL] [Abstract][Full Text] [Related]
4. Mutations in genes encoding polycomb repressive complex 2 subunits cause Weaver syndrome.
Imagawa E; Higashimoto K; Sakai Y; Numakura C; Okamoto N; Matsunaga S; Ryo A; Sato Y; Sanefuji M; Ihara K; Takada Y; Nishimura G; Saitsu H; Mizuguchi T; Miyatake S; Nakashima M; Miyake N; Soejima H; Matsumoto N
Hum Mutat; 2017 Jun; 38(6):637-648. PubMed ID: 28229514
[TBL] [Abstract][Full Text] [Related]
5. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders.
Ernst T; Chase AJ; Score J; Hidalgo-Curtis CE; Bryant C; Jones AV; Waghorn K; Zoi K; Ross FM; Reiter A; Hochhaus A; Drexler HG; Duncombe A; Cervantes F; Oscier D; Boultwood J; Grand FH; Cross NC
Nat Genet; 2010 Aug; 42(8):722-6. PubMed ID: 20601953
[TBL] [Abstract][Full Text] [Related]
6. EZH2 in Myeloid Malignancies.
Rinke J; Chase A; Cross NCP; Hochhaus A; Ernst T
Cells; 2020 Jul; 9(7):. PubMed ID: 32650416
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of polycomb repressive complex 2 key components EZH2/SUZ12/EED as an unfavorable prognostic marker in cholangiocarcinoma.
Wasenang W; Puapairoj A; Settasatian C; Proungvitaya S; Limpaiboon T
Pathol Res Pract; 2019 Jul; 215(7):152451. PubMed ID: 31126817
[TBL] [Abstract][Full Text] [Related]
8. SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex.
Cao R; Zhang Y
Mol Cell; 2004 Jul; 15(1):57-67. PubMed ID: 15225548
[TBL] [Abstract][Full Text] [Related]
9. Deregulated Polycomb functions in myeloproliferative neoplasms.
Sashida G; Oshima M; Iwama A
Int J Hematol; 2019 Aug; 110(2):170-178. PubMed ID: 30706327
[TBL] [Abstract][Full Text] [Related]
10. Genetic defects in PRC2 components other than EZH2 are not common in myeloid malignancies.
Kroeze LI; Nikoloski G; da Silva-Coelho P; van Hoogen P; Stevens-Linders E; Kuiper RP; Schnittger S; Haferlach T; Pahl HL; van der Reijden BA; Jansen JH
Blood; 2012 Feb; 119(5):1318-9. PubMed ID: 22308284
[No Abstract] [Full Text] [Related]
11. Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity.
Pasini D; Bracken AP; Jensen MR; Lazzerini Denchi E; Helin K
EMBO J; 2004 Oct; 23(20):4061-71. PubMed ID: 15385962
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the expression pattern of the PRC2 core subunit Suz12 during embryonic development of Xenopus laevis.
Aldiri I; Vetter ML
Dev Dyn; 2009 Dec; 238(12):3185-92. PubMed ID: 19877271
[TBL] [Abstract][Full Text] [Related]
13. A Family of Vertebrate-Specific Polycombs Encoded by the LCOR/LCORL Genes Balance PRC2 Subtype Activities.
Conway E; Jerman E; Healy E; Ito S; Holoch D; Oliviero G; Deevy O; Glancy E; Fitzpatrick DJ; Mucha M; Watson A; Rice AM; Chammas P; Huang C; Pratt-Kelly I; Koseki Y; Nakayama M; Ishikura T; Streubel G; Wynne K; Hokamp K; McLysaght A; Ciferri C; Di Croce L; Cagney G; Margueron R; Koseki H; Bracken AP
Mol Cell; 2018 May; 70(3):408-421.e8. PubMed ID: 29628311
[TBL] [Abstract][Full Text] [Related]
14. EZH2 mutations and promoter hypermethylation in childhood acute lymphoblastic leukemia.
Schäfer V; Ernst J; Rinke J; Winkelmann N; Beck JF; Hochhaus A; Gruhn B; Ernst T
J Cancer Res Clin Oncol; 2016 Jul; 142(7):1641-50. PubMed ID: 27169594
[TBL] [Abstract][Full Text] [Related]
15. PRC2-complex related dysfunction in overgrowth syndromes: A review of EZH2, EED, and SUZ12 and their syndromic phenotypes.
Cyrus S; Burkardt D; Weaver DD; Gibson WT
Am J Med Genet C Semin Med Genet; 2019 Dec; 181(4):519-531. PubMed ID: 31724824
[TBL] [Abstract][Full Text] [Related]
16. Somatic mutations of calreticulin in patients with myelodysplastic/myeloproliferative neoplasms-unclassifiable.
Zhang X; Pan J
Ann Hematol; 2017 Nov; 96(11):1949-1951. PubMed ID: 28819904
[No Abstract] [Full Text] [Related]
17. The murine polycomb group protein Eed is required for global histone H3 lysine-27 methylation.
Montgomery ND; Yee D; Chen A; Kalantry S; Chamberlain SJ; Otte AP; Magnuson T
Curr Biol; 2005 May; 15(10):942-7. PubMed ID: 15916951
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
Fiskus W; Pranpat M; Balasis M; Herger B; Rao R; Chinnaiyan A; Atadja P; Bhalla K
Mol Cancer Ther; 2006 Dec; 5(12):3096-104. PubMed ID: 17172412
[TBL] [Abstract][Full Text] [Related]
19. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
[TBL] [Abstract][Full Text] [Related]
20. Discovery of selective activators of PRC2 mutant EED-I363M.
Suh JL; Barnash KD; Abramyan TM; Li F; The J; Engelberg IA; Vedadi M; Brown PJ; Kireev DB; Arrowsmith CH; James LI; Frye SV
Sci Rep; 2019 Apr; 9(1):6524. PubMed ID: 31024026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
